Mential

Mential is clinical data infrastructure for real-world evidence in chronic disease and comorbidity.

We capture multimodal signals where no clinical record exists today — between visits, between episodes, between the moments pharma needs to see and currently cannot. Video sessions, in-app behavior, passive mobile sensors, and validated clinical instruments are structured into 1,700+ FHIR R4 markers, natively mapped to SNOMED CT and LOINC, generating longitudinal patient profiles with continuous comorbidity tracking and behavioral evolution measurable across the full treatment arc.

The structural problem we solve for pharma: clinical trials run blind between visits. Dropout is invisible until week four. Comorbidity surfaces as an adverse event rather than a monitored variable. Two active regulatory mandates make this gap urgent now — EMA and FDA require sex-disaggregated data in every dossier (in force 2024), and the EU HTA Regulation (January 2025) requires real-world quality-of-life evidence for Joint Clinical Assessments. No structured European dataset exists that responds to both simultaneously.

Three entry points for pharma:

• RWE Observational Studies — Mential designs and executes 12-week studies delivering publishable FHIR R4 cohort data for regulatory dossiers. €80–150K per study.

• Biomarker Validation — Cross-reference a candidate biomarker against 1,300+ FHIR markers across 54,000 patients to identify correlation patterns and stratification signals. €40–80K.

• Digital Endpoint Co-Development — Validated assessment battery and remote monitoring infrastructure for Phase II–III trial endpoints. Co-development fee + royalty model.